KaloBios Pharmaceuticals, Inc.' Targeted Antibacterial KB001-A to be Featured in Biotechnology Industry Organization (BIO) 2013 Panel Discussion of "New Defenses Against Old Enemies"  
4/18/2013 6:35:02 AM

SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."


Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.

Breakout Session: Innovations and Opportunities in Vaccines
Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
When:Tuesday, April 23, 2013, 9:00 10:15 AM
Where: McCormick Place, Room S402A

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415) 690-0210

SOURCE KaloBios Pharmaceuticals